Staff
Pfizer has announced that it made a preliminary bid to acquire U.K.-based AstraZeneca in January and tried to restart merger talks over the weekend, but was rebuffed.
Pfizer chairman and CEO Ian Reid says the US$100-billion dollar deal “could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients.”
However, AstraZeneca’s board remains confident in the ongoing execution of the company’s strategy as an independent company and that its successful delivery will create significant value for shareholders.
Pfizer is currently considering its options with respect to AstraZeneca.
Related article: